Nephron To Receive $7.9M To End Trade Secrets Case
U.S. Compounding Inc. and its parent Adamis Pharmaceuticals Corp. have agreed to pay $7.9 million as part of a deal to end a lawsuit by Nephron Pharmaceuticals Corp. claiming they stole...To view the full article, register now.
Already a subscriber? Click here to view full article